Review



human mertk peptide  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    R&D Systems human mertk peptide
    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in <t>MERTK-expressing</t> AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE <t>and</t> <t>monoclonal</t> antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated
    Human Mertk Peptide, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Human+C-Peptide+Antibody/pmc13032267-67-15-18
    Average 94 stars, based on 14 article reviews
    human mertk peptide - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia"

    Article Title: RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/s13046-026-03657-y

    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE and monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated
    Figure Legend Snippet: The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE and monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated

    Techniques Used: Activity Assay, Expressing, Staining, Flow Cytometry

    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML primary cells. A - D Bar graphs show the percentage of relative luminescence in primary AML cells, RGX946 ( A ), RGX694 ( B ), RGX702 ( C ), and RGX470 ( D ) treated with the indicated concentrations of RGX-019-MMAE or the monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). E Representative figures of colony-forming units for normal peripheral blood mononuclear cells in response to DMSO and indicated concentrations of RGX-019-MMAE and RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test) * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001
    Figure Legend Snippet: The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML primary cells. A - D Bar graphs show the percentage of relative luminescence in primary AML cells, RGX946 ( A ), RGX694 ( B ), RGX702 ( C ), and RGX470 ( D ) treated with the indicated concentrations of RGX-019-MMAE or the monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). E Representative figures of colony-forming units for normal peripheral blood mononuclear cells in response to DMSO and indicated concentrations of RGX-019-MMAE and RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test) * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001

    Techniques Used: Activity Assay, Expressing

    Related Articles

    other:

    Article Title: A feeding-induced myokine modulates glucose homeostasis.
    Article Snippet: Maintaining blood glucose homeostasis during fasting and feeding is crucial for the prevention of dysregulation that can lead to either hypoor hyperglycaemia.. Here we identified feimin, encoded by a gene with a previously unknown function (B230219D22Rik in mice, C5orf24 in humans), as a key modulator of glucose homeostasis.. Feimin is secreted from skeletal muscle during feeding and binds to its receptor, receptor protein tyrosine kinase Mer (MERTK), promoting glucose uptake and inhibiting glucose production by activation of AKT.

    Article Title: Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice
    Article Snippet: Then the 549 membranes were blocked with 5% non-fat milk in TBST and immunostained with primary 550 antibodies, anti-p-Syk (cell signaling technology 2710s, 1:1000), anti-Syk (cell signaling 551 technology 13198, 1:1000), anti-p-AKT (cell signaling technology 4060s, 1:1000) anti-552 AKT (cell signaling technology 4685, 1:1000), anti-cleaved Gasdermin D (cell signaling 553 technology 10137S, 1:1000), anti-p-β-Catenin (cell signaling technology 5651, 1:1000), 554 anti-β-Catenin (cell signaling technology 8480S, 1:1000), anti-PDGFB (abcam 555 ab23914,1:1000), anti-Histone H3 (cell signaling technology 4499, 1:1000), anti-MERTK 556 27 (R&D system AF591, 1:1000), and β-actin (cell signaling technology 4970s, 1:5000) at 557 4°C overnight and detected using HRP-conjugated secondary antibodies.

    Article Title: Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice
    Article Snippet: Then, the membranes were blocked with 5% nonfat milk in TBST and immunostained with the primary antibodies anti–p-Syk (Cell Signaling Technology, 2710s, 1:1,000), anti-Syk (Cell Signaling Technology, 13198, 1:1,000), anti–p-AKT (Cell Signaling Technology, 4060s, 1:1,000), anti-AKT (Cell Signaling Technology, 4685, 1:1,000), anti–cleaved gasdermin D (Cell Signaling Technology, 10137S, 1:1,000), anti–p–β-catenin (Cell Signaling Technology, 5651, 1:1,000), anti–β-catenin (Cell Signaling Technology, 8480S, 1:1,000), anti-PDGFB (Abcam, ab23914,1:1,000), anti–histone H3 (Cell Signaling Technology, 4499, 1:1,000), anti-MERTK (R&D Systems, AF591, 1:1,000), and β-actin (Cell Signaling Technology, 4970s, 1:5,000) at 4°C overnight and detected using HRP-conjugated secondary antibodies.

    Bioprocessing:

    Article Title: Cardiac Macrophages Promote Polarization of Macrophages toward M2 Phenotype to Improve Myocardial Remodeling via NGAL after Myocardial Infarction.
    Article Snippet: Several studies have shown that the number of circulating neutrophils or the levels of their secreted factors, including Neutrophil Gelatinase-Associated Lipocalin (NGAL), in plasma are associated with the prognosis and mortality of patients with myocardial infarction (MI).. However, the underlying mechanisms remain unclear.. MI was induced in mice by permanent ligation of the left anterior descending coronary artery.

    Immunoprecipitation:

    Article Title: Exploiting structural variability in the kinase back-pocket to modulate polypharmacology of TAM inhibitors.
    Article Snippet: TAM kinases play dual roles in tumor cells and the innate immune system.. While they have redundant functions, the TAM kinases are differentially required in specific contexts.. Therefore, inhibition of specific TAM kinases or pairs of TAM kinases will be desirable in different tumor types.

    Article Title: Discovery of Novel TYRO3/MERTK Dual Inhibitors.
    Article Snippet: The TAM (TYRO3, AXL, MERTK) family of receptor tyrosine kinases has roles in oncogenesis and innate immunity, but the relative importance of the family members can differ in different contexts and between tumor types or individual tumors.. Dual TYRO3 and MERTK inhibition may be advantageous for treatment of diseases or in tumors that are dependent on their coordinated action.. Here, we report the discovery of the first potent dual TYRO3/MERTK inhibitor, UNC9435 (44).

    Staining:

    Article Title: MerTK is a mediator of alpha-synuclein fibril uptake by human microglia
    Article Snippet: .. Cells were blocked with Human TrueStain FcX and TrueStain Monocyte Blocker (Biolegend) and stained with the following antibodies: anti-AXL clone #108724 and anti-MERTK clone #125518 (R&D Systems). .. Cells were blocked with Human TrueStain FcX and TrueStain Monocyte Blocker (Biolegend) and stained with the following antibodies: anti-AXL clone #108724 and anti-MERTK clone #125518 (R&D Systems).

    Article Title: Systematic comparison of culture media uncovers phenotypic shift of primary human microglia defined by reduced reliance to CSF1R signaling.
    Article Snippet: Funding information Montreal Neurological Institute New Investigator Fund; Canadian Institutes of Health Research (CIHR) Abstract Efforts to understand microglia function in health and diseases have been hindered by the lack of culture models that recapitulate in situ cellular properties.. In recent years, the use of serum-free media with brain-derived growth factors (colony stimulating factor 1 receptor [CSF1R] ligands and TGF-β1/2) have been favored for the maintenance of rodent microglia as they promote morphological features observed in situ.. Here we study the functional and transcriptomic impacts of such media on human microglia (hMGL). .. Funding information Montreal Neurological Institute New Investigator Fund; Canadian Institutes of Health Research (CIHR) Abstract Efforts to understand microglia function in health and diseases have been hindered by the lack of culture models that recapitulate in situ cellular properties.. In recent years, the use of serum-free media with brain-derived growth factors (colony stimulating factor 1 receptor [CSF1R] ligands and TGF-β1/2) have been favored for the maintenance of rodent microglia as they promote morphological features observed in situ.. Here we study the functional and transcriptomic impacts of such media on human microglia (hMGL). ..



    Similar Products

    94
    Cell Signaling Technology Inc mertk
    (A) Split Umap subclustering of PMNC from 2153L CTX treated, 2153L untreated (VC), T12 CTX treated, and T12 untreated (Left to Right) scRNAseq datasets. (B) Ucell signature scoring for Phagocytosis, MHCI, MHCII, T Cell Activation, and IFN response across MP populations. (C) Schematic showing myeloid cell expressing TAMRTKs and MRX-2843 inhibition. (D) Western blot of total <t>MerTK</t> (tMertk), <t>total</t> <t>Axl</t> (tAxl), phospho-Erk (pErk), and β-actin from T12 and 2153L in vitro cultured cancer cells or TAM protein lysates. TAMs were isolated from tumors and cultured in vitro. (E) Non-linear regression plot of CellTiter-Glo analysis of viability in both T12 and 2153L across increasing doses of MRX-2843 to determine IC50s for each cell line. (F) Treatment strategy for CTX and MRX-2843 long-term response study. (G) 2153L tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups VC (n=7), MRX-2843 (n=8), CTX (n=6), Combo (n=7). (p=0.0014, 0.0012, 0.0009, respectively) (H) T12 tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups. Kaplan-Meier curves analyzed using log-rank test. VC (n=7), MRX-2843 (n=7), CTX (n=6), Combo (n=6). (p< 0.0001 for all groups). Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    Mertk, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Mer+Rabbit+mAb/pmc13584615-100-24-28
    Average 94 stars, based on 1 article reviews
    mertk - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    Miltenyi Biotec mertk
    (A) Split Umap subclustering of PMNC from 2153L CTX treated, 2153L untreated (VC), T12 CTX treated, and T12 untreated (Left to Right) scRNAseq datasets. (B) Ucell signature scoring for Phagocytosis, MHCI, MHCII, T Cell Activation, and IFN response across MP populations. (C) Schematic showing myeloid cell expressing TAMRTKs and MRX-2843 inhibition. (D) Western blot of total <t>MerTK</t> (tMertk), <t>total</t> <t>Axl</t> (tAxl), phospho-Erk (pErk), and β-actin from T12 and 2153L in vitro cultured cancer cells or TAM protein lysates. TAMs were isolated from tumors and cultured in vitro. (E) Non-linear regression plot of CellTiter-Glo analysis of viability in both T12 and 2153L across increasing doses of MRX-2843 to determine IC50s for each cell line. (F) Treatment strategy for CTX and MRX-2843 long-term response study. (G) 2153L tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups VC (n=7), MRX-2843 (n=8), CTX (n=6), Combo (n=7). (p=0.0014, 0.0012, 0.0009, respectively) (H) T12 tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups. Kaplan-Meier curves analyzed using log-rank test. VC (n=7), MRX-2843 (n=7), CTX (n=6), Combo (n=6). (p< 0.0001 for all groups). Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .
    Mertk, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Mer+Antibody%2C+anti-mouse%2C+REAfinity/pm42520061-48-73-75
    Average 93 stars, based on 1 article reviews
    mertk - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    ABclonal Biotechnology mertk rabbit pab
    a Schematic illustration of the pro-efferocytosis property of MMAzyme-S. (Created in BioRender. Huang, H. (2026) https://BioRender.com/7l5dwq4 ). b CLSM images depicting phagocytosis of CD47-overexpressed ACs in proinflammatory-phenotype macrophages pretreated with different samples. FCM results ( c ) and the corresponding quantitative analysis ( d ) of efferocytosis towards CD47-overexpressed ACs by proinflammatory phenotype macrophages pretreated with different samples ( n = 3 independent biological samples). e The quantitative results of the Western blotting of <t>Mertk</t> in macrophages under different treatments ( n = 3 independent biological samples. Samples in different blots were derived from the same experiment. All gels/blots were processed in parallel. f Schematics illustration for the mechanism of promoting cholesterol efflux mediated by MMAzyme-S (created in BioRender. Huang, H. (2026) https://BioRender.com/o3x56t5 ). g Optical microscopy images of induced foamy cell formation in macrophages under different treatments. h Cholesterol content in the supernatant of foamy cells under different treatments ( n = 4 independent biological samples). i Western blotting analysis of Mertk, <t>PPARγ,</t> <t>LXRα,</t> ABCA1, and ABCG1 in macrophages under different treatments. Corresponding quantitative results of the Western blotting of PPARγ ( j ), LXRα ( k ), ABCA1 ( l ), and ABCG1 ( m ) in macrophages under different treatments ( n = 3 independent biological samples. Samples in different blots were derived from the same experiment. All gels/blots were processed in parallel). Data in ( d , e , h , j – m ) were expressed as mean ± S.D. Significance in ( d , e , h , j – m ) was calculated using one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. Although the individual values of Group ii and Group iii in ( l ) do not overlap, the statistical analysis does not indicate a significant difference, possibly due to the limited sample size. Source data are provided as a file.
    Mertk Rabbit Pab, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/MERTK+Rabbit+pAb/pmc13507257-445-29-33
    Average 93 stars, based on 1 article reviews
    mertk rabbit pab - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    R&D Systems human mertk peptide
    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in <t>MERTK-expressing</t> AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE <t>and</t> <t>monoclonal</t> antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated
    Human Mertk Peptide, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Human+C-Peptide+Antibody/pmc13032267-67-15-18
    Average 94 stars, based on 1 article reviews
    human mertk peptide - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    R&D Systems mouse igg1 kappa light chain mertk
    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in <t>MERTK-expressing</t> AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE <t>and</t> <t>monoclonal</t> antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated
    Mouse Igg1 Kappa Light Chain Mertk, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Mouse+IgG1+Antibody/pmc13032267-67-0-18
    Average 95 stars, based on 1 article reviews
    mouse igg1 kappa light chain mertk - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc rabbit anti phospho mertk antibody
    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in <t>MERTK-expressing</t> AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE <t>and</t> <t>monoclonal</t> antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated
    Rabbit Anti Phospho Mertk Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Phospho-Axl+(Tyr698)%2FMer+(Tyr749)%2FTyro3+(Tyr681)+Rabbit+mAb/pm40903592-487-23-27
    Average 94 stars, based on 1 article reviews
    rabbit anti phospho mertk antibody - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems mertk
    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in <t>MERTK-expressing</t> AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE <t>and</t> <t>monoclonal</t> antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated
    Mertk, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Mouse+Mer+Antibody/pm41887381-56-9-14
    Average 93 stars, based on 1 article reviews
    mertk - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems mertk antibody
    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in <t>MERTK-expressing</t> AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE <t>and</t> <t>monoclonal</t> antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated
    Mertk Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+mertk/Human+Mer+Antibody/pm41798920-77-10-12
    Average 93 stars, based on 1 article reviews
    mertk antibody - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results


    (A) Split Umap subclustering of PMNC from 2153L CTX treated, 2153L untreated (VC), T12 CTX treated, and T12 untreated (Left to Right) scRNAseq datasets. (B) Ucell signature scoring for Phagocytosis, MHCI, MHCII, T Cell Activation, and IFN response across MP populations. (C) Schematic showing myeloid cell expressing TAMRTKs and MRX-2843 inhibition. (D) Western blot of total MerTK (tMertk), total Axl (tAxl), phospho-Erk (pErk), and β-actin from T12 and 2153L in vitro cultured cancer cells or TAM protein lysates. TAMs were isolated from tumors and cultured in vitro. (E) Non-linear regression plot of CellTiter-Glo analysis of viability in both T12 and 2153L across increasing doses of MRX-2843 to determine IC50s for each cell line. (F) Treatment strategy for CTX and MRX-2843 long-term response study. (G) 2153L tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups VC (n=7), MRX-2843 (n=8), CTX (n=6), Combo (n=7). (p=0.0014, 0.0012, 0.0009, respectively) (H) T12 tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups. Kaplan-Meier curves analyzed using log-rank test. VC (n=7), MRX-2843 (n=7), CTX (n=6), Combo (n=6). (p< 0.0001 for all groups). Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .

    Journal: Cancer immunology research

    Article Title: MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9 + monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer

    doi: 10.1158/2326-6066.CIR-26-0278

    Figure Lengend Snippet: (A) Split Umap subclustering of PMNC from 2153L CTX treated, 2153L untreated (VC), T12 CTX treated, and T12 untreated (Left to Right) scRNAseq datasets. (B) Ucell signature scoring for Phagocytosis, MHCI, MHCII, T Cell Activation, and IFN response across MP populations. (C) Schematic showing myeloid cell expressing TAMRTKs and MRX-2843 inhibition. (D) Western blot of total MerTK (tMertk), total Axl (tAxl), phospho-Erk (pErk), and β-actin from T12 and 2153L in vitro cultured cancer cells or TAM protein lysates. TAMs were isolated from tumors and cultured in vitro. (E) Non-linear regression plot of CellTiter-Glo analysis of viability in both T12 and 2153L across increasing doses of MRX-2843 to determine IC50s for each cell line. (F) Treatment strategy for CTX and MRX-2843 long-term response study. (G) 2153L tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups VC (n=7), MRX-2843 (n=8), CTX (n=6), Combo (n=7). (p=0.0014, 0.0012, 0.0009, respectively) (H) T12 tumor volume comparisons across treatments during 30 days of treatment. KM plot of overall survival across treatment groups. Kaplan-Meier curves analyzed using log-rank test. VC (n=7), MRX-2843 (n=7), CTX (n=6), Combo (n=6). (p< 0.0001 for all groups). Created in BioRender. Zhao, N. (2026) https://BioRender.com/e6uqj0s .

    Article Snippet: Blots were blocked with 5% non-fat dry milk (BioRad, 1706404) in PBS, then probed with the following antibodies in 5% BSA (Sigma-Aldrich, A7906) solution: MERTK (Cell Signaling Technology (CST), 38102), AXL (CST, 8661, RRID:AB_11217435), p44/42 (CST, 9102, RRID:AB_330744), p-p44/42 (CST, 9101, RRID:AB_331646), iNOS (CST, 13120, RRID:AB_2799268), PD-L1 (R&D Systems, AF1019, RRID:AB_354540), p-STAT1 (CST, 8062, RRID:AB_10949108), Arg1(CST, 93668, RRID:AB_2800207), and SOCS1 (CST, 55313).

    Techniques: Activation Assay, Expressing, Inhibition, Western Blot, In Vitro, Cell Culture, Isolation, Analysis

    a Schematic illustration of the pro-efferocytosis property of MMAzyme-S. (Created in BioRender. Huang, H. (2026) https://BioRender.com/7l5dwq4 ). b CLSM images depicting phagocytosis of CD47-overexpressed ACs in proinflammatory-phenotype macrophages pretreated with different samples. FCM results ( c ) and the corresponding quantitative analysis ( d ) of efferocytosis towards CD47-overexpressed ACs by proinflammatory phenotype macrophages pretreated with different samples ( n = 3 independent biological samples). e The quantitative results of the Western blotting of Mertk in macrophages under different treatments ( n = 3 independent biological samples. Samples in different blots were derived from the same experiment. All gels/blots were processed in parallel. f Schematics illustration for the mechanism of promoting cholesterol efflux mediated by MMAzyme-S (created in BioRender. Huang, H. (2026) https://BioRender.com/o3x56t5 ). g Optical microscopy images of induced foamy cell formation in macrophages under different treatments. h Cholesterol content in the supernatant of foamy cells under different treatments ( n = 4 independent biological samples). i Western blotting analysis of Mertk, PPARγ, LXRα, ABCA1, and ABCG1 in macrophages under different treatments. Corresponding quantitative results of the Western blotting of PPARγ ( j ), LXRα ( k ), ABCA1 ( l ), and ABCG1 ( m ) in macrophages under different treatments ( n = 3 independent biological samples. Samples in different blots were derived from the same experiment. All gels/blots were processed in parallel). Data in ( d , e , h , j – m ) were expressed as mean ± S.D. Significance in ( d , e , h , j – m ) was calculated using one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. Although the individual values of Group ii and Group iii in ( l ) do not overlap, the statistical analysis does not indicate a significant difference, possibly due to the limited sample size. Source data are provided as a file.

    Journal: Nature Communications

    Article Title: Bioinspired porous metal-amino acid nanozymes enable multi-pathway treatment of atherosclerosis through anti-oxidation and pro-efferocytosis

    doi: 10.1038/s41467-026-75509-4

    Figure Lengend Snippet: a Schematic illustration of the pro-efferocytosis property of MMAzyme-S. (Created in BioRender. Huang, H. (2026) https://BioRender.com/7l5dwq4 ). b CLSM images depicting phagocytosis of CD47-overexpressed ACs in proinflammatory-phenotype macrophages pretreated with different samples. FCM results ( c ) and the corresponding quantitative analysis ( d ) of efferocytosis towards CD47-overexpressed ACs by proinflammatory phenotype macrophages pretreated with different samples ( n = 3 independent biological samples). e The quantitative results of the Western blotting of Mertk in macrophages under different treatments ( n = 3 independent biological samples. Samples in different blots were derived from the same experiment. All gels/blots were processed in parallel. f Schematics illustration for the mechanism of promoting cholesterol efflux mediated by MMAzyme-S (created in BioRender. Huang, H. (2026) https://BioRender.com/o3x56t5 ). g Optical microscopy images of induced foamy cell formation in macrophages under different treatments. h Cholesterol content in the supernatant of foamy cells under different treatments ( n = 4 independent biological samples). i Western blotting analysis of Mertk, PPARγ, LXRα, ABCA1, and ABCG1 in macrophages under different treatments. Corresponding quantitative results of the Western blotting of PPARγ ( j ), LXRα ( k ), ABCA1 ( l ), and ABCG1 ( m ) in macrophages under different treatments ( n = 3 independent biological samples. Samples in different blots were derived from the same experiment. All gels/blots were processed in parallel). Data in ( d , e , h , j – m ) were expressed as mean ± S.D. Significance in ( d , e , h , j – m ) was calculated using one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. Although the individual values of Group ii and Group iii in ( l ) do not overlap, the statistical analysis does not indicate a significant difference, possibly due to the limited sample size. Source data are provided as a file.

    Article Snippet: The following primary antibodies were used in this study: CD47 Rabbit pAb (A1838, ABclonal,1:750), CD36/SR-B3 Rabbit pAb (A5792, ABclonal,1:2500), CCR2 Rabbit pAb (A2855, ABclonal,1:750), Na-K-ATP Rabbit pAb (GB11400, Servicebio,1:2000), MERTK Rabbit pAb (A5443, ABclonal,1:750), LXRα Rabbit mAb (A3974, ABclonal,1:3000), ABCG1 Rabbit mAb (A17907, ABclonal,1:1500), PPARγ Rabbit pAb (WL01800, Wanleibio,1:1000), Anti-ABCA1 antibody ( AB307536 , Abcam,1:1000), GAPDH Rabbit pAb (AC001, ABclonal,1:20000), p-SHP1 (8849, Cell Signaling Technology, 1:1000), HRP-conjugated Goat anti-Rabbit IgG (H+L) (AS014, ABclonal,1:5000).

    Techniques: Western Blot, Derivative Assay, Microscopy

    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE and monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia

    doi: 10.1186/s13046-026-03657-y

    Figure Lengend Snippet: The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML cell lines. A MERTK expression in the indicated AML cell lines; leukemic cells (1 × 10 6 ) were stained with anti-MERTK-APC antibody, and the expression was measured by flow cytometry. Data are plotted as mean values with error bars representing standard error. B - F Bar graph showing the percentage of relative luminescence in Kasumi 1 ( B ), OCI-AML3 ( C ), MOLM-13 ( D ), MOLM-14 ( E ), and MV4-11 ( F ) cells treated with the indicated concentrations of RGX-019-MMAE and monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001. UT = untreated

    Article Snippet: Mouse IgG1/kappa light chain MERTK-specific monoclonal antibodies were generated in mice by immunization with Fc-tagged human MERTK peptide (R&D Systems, Minneapolis, MN) USA).

    Techniques: Activity Assay, Expressing, Staining, Flow Cytometry

    The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML primary cells. A - D Bar graphs show the percentage of relative luminescence in primary AML cells, RGX946 ( A ), RGX694 ( B ), RGX702 ( C ), and RGX470 ( D ) treated with the indicated concentrations of RGX-019-MMAE or the monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). E Representative figures of colony-forming units for normal peripheral blood mononuclear cells in response to DMSO and indicated concentrations of RGX-019-MMAE and RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test) * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia

    doi: 10.1186/s13046-026-03657-y

    Figure Lengend Snippet: The antibody-drug conjugate RGX-019-MMAE induced cytotoxic activity in MERTK-expressing AML primary cells. A - D Bar graphs show the percentage of relative luminescence in primary AML cells, RGX946 ( A ), RGX694 ( B ), RGX702 ( C ), and RGX470 ( D ) treated with the indicated concentrations of RGX-019-MMAE or the monoclonal antibody RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test). E Representative figures of colony-forming units for normal peripheral blood mononuclear cells in response to DMSO and indicated concentrations of RGX-019-MMAE and RGX-019. Data are plotted as mean values with error bars representing standard error (Student unpaired t -test) * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001

    Article Snippet: Mouse IgG1/kappa light chain MERTK-specific monoclonal antibodies were generated in mice by immunization with Fc-tagged human MERTK peptide (R&D Systems, Minneapolis, MN) USA).

    Techniques: Activity Assay, Expressing